Jupiter CEO Maarten Slendebroek reiterated that future flows will be “less predictable” as Jupiter diversifies its business away from the UK market, while addressing the firm’s other issues like its gender pay gap.
Schroders is the latest manager to report a hit to total assets over the first quarter as fund groups cope with higher volatility.
Aberdeen Standard Investments has joined Royal London Asset Management (RLAM) in voting against Persimmon’s remuneration package, which it said threatens the firm’s reputation.
Lloyds’ share price remained depressed, despite delivering a good set of first quarter figures, containing higher profits as Payment Protection Insurance (PPI) costs fall.
Despite Brexit uncertainty and a more dovish tone from the Bank of England (BoE), many managers are arguing that now is the time to embrace the big four UK banks as a cheap, tactical value play.
Neil Woodford has highlighted his track record for backing biotech winners in his Patient Capital Trust annual review, just one day after Prothena’s share price blow-up.
Nick Train has argued he hasn’t missed out “on the transformative changes in technology”, despite owning few pure tech companies in his Lindsell Train Investment Trust.
Neil Woodford has said he will continue to back American biotech firm Prothena, as it reels from the decision to halt development on its star drug, which failed key clinical tests.
Capita’s share price has rallied after the firm confirmed a £701m rights issue and more than £500m in net losses, but analysts remain cautious on recommending the stock.
Barclays CEO Jes Staley is facing a fine for an alleged breach of conduct in his attempts to uncover a 2016 whistleblower but will be allowed to keep his job.
Lopsided net flows into Jupiter Asset Management’s Dynamic Bond and Strategic Bond mirror strategies has been attributed to UK investors’ brand loyalty through bouts of underperformance.
The Financial Conduct Authority (FCA) has agreed to review the preference share market following investor backlash from the Aviva “debacle,” which saw the insurer backtrack on its plans to cancel preference shares at par value.
